drugset
drugset / Trial / NCT04221828

Trial of NanoPac Focal Therapy for Prostate Cancer

NCT04221828 ↗

Phase 2 Terminated 1 enrolled NanOlogy, LLC US Biotest, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.

Timeline

Start
2020-10-20
Primary completion
2021-01-27
Completion
2021-02-08

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject NanoPac® Unknown 15 mg/ml Other

Indications

prostate adenocarcinoma